000 04106nam a22005537a 4500
008 140202b ck ||||| |||| 00| 0 spa d
020 _a92 4 159484 5 -- 978 92 4 159484 4
082 0 4 _a618.88 / W551f
110 1 _aWHO - World Health Organization
_994155
245 1 0 _aFrequently asked clinical questions about medical abortion : conclusions of an International Consensus
245 1 0 _aConference on Medical Abortion in early first trimestre, Bellagio, Italy
264 _a[Geneva] : World Health Organization, 2006
300 _a35 p. ; 21 x 15 cm.
505 0 0 _aPre-abortion care -- What couynselling is needed by a woman with an unwanted pregnancy who is contemplating
505 0 0 _aabortion? -- What factors should be taken into account when counselling a woman about her choice between
505 0 0 _amedical and surgical abortion? -- What are the contraindications to medical abortion? -- Do any other
505 0 0 _acharacteristics of the woman need to be taken into account in providing medical abortion? -- How should
505 0 0 _apregnancy be confirmed ant gestation estimated? -- What clinical assessment an laboratory investigations are
505 0 0 _arequired prior to medical abortion? -- What steps are necessary to minimize the risk of undiagnosed ectopic
505 0 0 _apregnancy? -- Regimen for medical abortion -- What is the recommended regimen for medical abortion? -- Are
505 0 0 _aother doses of mifepristone possible? -- Are other doses or routes of administration of the prostaglandin
505 0 0 _apossible? -- What are the advantages and disadvantages of misoprostol versus gemeprost? -- Can other
505 0 0 _aprostaglandins be used? -- Is the interval between administration of mifepristone and prostaglandin crucial?
505 0 0 _a-- Can abortion Be Induced using prostaglandin alone? -- What pain relief should Be available to women during
505 0 0 _amedical abortion? -- Postabortion care -- If a woman has an incomplete abortion, is it necessary to evacuate
505 0 0 _athe uterus surgically? -- How should pelvic infection be diagnosed and treated after abortion? -- How should
505 0 0 _athe success of medical abortion be confirmed? -- How should ectopic pregnancy be identified after medical
505 0 0 _aabortion? -- Is there a risk of fetal anormality after an unsuccessful medical abortion? -- Which methodos of
505 0 0 _acontraception can a woman use after medical abortion? -- Issues related to provision of medical abortion
505 0 0 _aservices -- Legal and regulatory issues -- Setting up a medical abortion service -- Obtaining the necessary
505 0 0 _amedicines -- Annex --
520 _aOn 1-5 November 2004, in Bellagio, Italy, the UNDP/UNFPA/WHO/World Bank Special Programme of Research,
520 _aDevelopment and Research Training in Human Reproduction (HRP), organized a meeting entitled International
520 _aConsensus Conference on Non-surgical (Medical) Abortion in Early First Trimester on Issues Related to Regimens
520 _aand Service Delivery (Annex 1). This document is the result of the deliberations of the participants in that
520 _ameeting, who included highly experienced researchers and clinicians in the area of medical
520 _aabortion.--Background.
530 _ahttp://whqlibdoc.who.int/publications/2006/9241594845_eng.pdf (File size : 198 KB)
650 1 4 _aAborto inducido
_xmétodos
_999081
650 1 4 _aAgentes abortivos
_999698
650 1 4 _aServicios de la planificación familiar
_9131422
650 1 4 _aPlanificación familiar y reproducción humana
_9127715
650 1 4 _aSalud
_9130891
710 1 _aUNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human
_993782
710 1 _aReproduction
_993616
710 1 _aOMS - Organización Mundial de la Salud
_993453
711 _aInternational Consensus Conference on Non-surgical (Medical) Abortion in Early First Trimester on Issues
_994322
711 _aRelated to Regimens and Service Delivery (2004 : Bellagio, Italy)
_994363
999 _c24063
_d24063